Private company
TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc. is an American pharmaceutical preparations company based in Fort Worth.2
Last updated Oct 21, 2026.
Overview
- IndustryPharmaceutical Preparations2
- HeadquartersFort Worth, United States2
- Incorporated inDE3
- Business address2600 Via Fortuna, Suite 360, Austin, Tx 787463
- Filer category, Emerging growth company3
- Legal formCorporation2
- LEI549300YNXG7BW6IMHM872
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 67253672
See how the biggest companies compare on our leaderboards
Drugs. Combination drugs are products with two or more active pharmaceutical ingredients.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
-2983.4%Operating margin5
-2894.7%Net margin5
48.0%Revenue growth, 20235
-222.0%Return on equity5
-$16.1MFree cash flow5
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Research and development100¢$12.1M
- Interest0¢$14.5K
Out of $733.9K in revenue.5 The company lost money this year.
Financial statements
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | $88.2K6 | $495.8K5 | $733.9K5 | ||||
| Research and development | $848.8K7 | $8.8M8 | $10.7M9 | $21.3M6 | $18.5M5 | $12.1M5 | |
| Operating expenses | $31.9M6 | $32.3M5 | $22.6M5 | ||||
| Operating income | -$3.9M7 | -$12.0M8 | -$18.7M9 | -$31.8M6 | -$31.8M5 | -$21.9M5 | |
| Interest | $14.5K5 | ||||||
| Net income | -$3.8M7 | -$11.9M8 | -$18.6M9 | -$31.0M6 | -$31.8M5 | -$21.2M5 | |
| Earnings per share | -$1.256 | -$26.495 | -$11.855 | ||||
| Earnings per share (diluted) | -$1.256 | -$26.495 | -$11.855 | ||||
| Shares (weighted, basic) | 24.8M shares6 | 1.2M shares5 | 1.8M shares5 | ||||
| Shares (weighted, diluted) | 24.8M shares6 | 1.2M shares5 | 1.8M shares5 |
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Cash | $10.3M8 | $28.1M8 | $35.3M9 | $33.8M6 | $16.6M5 | $5.5M5 | |
| Current assets | $10.3M7 | $29.2M8 | $37.6M9 | $38.8M6 | $19.0M5 | $7.6M5 | |
| Property, plant and equipment | $1.9M6 | $3.1M5 | $2.0M5 | ||||
| Total assets | $10.4M7 | $29.2M8 | $38.7M9 | $40.7M6 | $24.1M5 | $12.0M5 | |
| Accounts payable | $1.5M6 | $919.6K5 | $958.4K5 | ||||
| Current liabilities | $1.2M7 | $410.6K8 | $1.3M8 | $2.0M6 | $1.1M5 | $2.4M5 | |
| Total liabilities | $1.2M7 | $1.5M8 | $1.3M9 | $2.0M6 | $1.2M5 | $2.5M5 | |
| Retained earnings | -$65.3M6 | -$97.1M5 | -$118.3M5 | ||||
| Shareholders’ equity | -$1.8K7 | -$3.2M8 | $27.6M9 | $37.3M6 | $38.7M5 | $22.9M5 | $9.6M5 |
| Shares outstanding | 4.0M shares7 | 18.5M shares8 | 22.5M shares9 | 25.4M shares6 | 1.4M shares5 | 2.4M shares5 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -$2.1M7 | -$11.2M8 | -$16.6M9 | -$29.6M6 | -$27.3M5 | -$16.0M5 | |
| Depreciation and amortization | $111.5K6 | $388.2K5 | $502.5K5 | ||||
| Stock-based compensation | $3.5M6 | $4.3M5 | $2.9M5 | ||||
| Capital spending | $1.1M9 | $868.5K6 | $1.6M5 | $94.8K5 | |||
| Free cash flow | -$17.7M | -$30.4M | -$28.9M | -$16.1M | |||
| Cash from investing | -$868.5K6 | -$1.6M5 | -$94.8K5 | ||||
| Cash from financing | $28.9M6 | $11.8M5 | $5.0M5 |
Corporate structure
TFF Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of TFF Pharmaceuticals, Inc.
- Carlson Capital, L.P. Filed SC 13G/A on TFF Pharmaceuticals, Inc., latest Nov 19, 2024 (4 filings since Nov 28, 2022)
- ARMISTICE CAPITAL, LLC Filed SC 13G on TFF Pharmaceuticals, Inc., latest Nov 14, 2024
- INTRACOASTAL CAPITAL, LLC Filed SC 13G on TFF Pharmaceuticals, Inc., latest May 8, 2024
- Laurence W. Lytton Filed SC 13G/A on TFF Pharmaceuticals, Inc., latest Feb 14, 2024 (3 filings since Nov 23, 2022)
- Lung Therapeutics, Inc. Filed SC 13G/A on TFF Pharmaceuticals, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
- Corriente Advisors, LLC Filed SC 13G/A on TFF Pharmaceuticals, Inc., latest Feb 14, 2022
- Nantahala Capital Management, LLC Filed SC 13G/A on TFF Pharmaceuticals, Inc., latest Feb 14, 2022
- TFF Pharmaceuticals, Inc. Fort Worth, Texas, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What TFF Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Construction in progress | $15 Dec 31, 2023 | $25 Dec 31, 2022 | −53.3% |
| Property and equipment, net | $2.0M5 Dec 31, 2023 | $3.1M5 Dec 31, 2022 | −35.0% |
| Operating-lease assets (leased space) | $119.5K5 Dec 31, 2023 | $196.0K5 Dec 31, 2022 | −39.0% |
Investments
Leadership
Who has led TFF Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerHarlan F. Weisman Dec 6, 2022 to Jul 8, 202412
- Chief executive officerGlenn R. Mattes Oct 24, 2019 to May 17, 202213
- PresidentHarlan F. Weisman Dec 6, 2022 to Jul 8, 202412
- PresidentGlenn R. Mattes Oct 24, 2019 to May 17, 202213
- Chief financial officerKirk Allen Coleman Oct 24, 2019 to Jul 8, 202414
- Chief operating officerChristopher Cano Sep 29, 2020 to Sep 24, 202115
Board members and other officers (14)
- Chief Medical OfficerZamaneh Mikhak Jan 20, 2023 to Jul 8, 202416
- Chief Science OfficerJames Brian Windsor Oct 24, 2019 to Dec 9, 202017
- Board memberCatherine Chai-Zon Lee Dec 4, 2023 to Jul 8, 202418
- Board memberMichael A. Patane Dec 4, 2023 to Apr 22, 202419
- Board memberThomas Braxton King Dec 15, 2023 to Jul 8, 202420
- Board memberBrandi Roberts Apr 4, 2022 to Jul 8, 202421
- Board memberMalcolm Fairbairn Feb 5, 2020 to May 19, 202122
- Board memberAaron G.l. Fletcher Oct 24, 2019 to Dec 30, 202223
- Board memberGlenn R. Mattes Oct 24, 2019 to May 17, 202213
- Board memberHarlan F. Weisman Oct 24, 2019 to Jul 8, 202424
- Board memberJames Brian Windsor Oct 24, 2019 to Dec 9, 202017
- Board memberRandy H. Thurman Oct 24, 2019 to Sep 30, 202225
- Board memberRobert S. Mills Oct 24, 2019 to Jul 8, 202426
- Board memberStephen Rocamboli Oct 24, 2019 to Jul 8, 202427
Timeline
- Mar 6, 20258-K Shareholder vote28
- Feb 3, 20258-K Unregistered sale of shares; Shareholder vote; Other events29
- Dec 10, 20248-K Listing notice or transfer30
- Nov 14, 20248-K Ended a material agreement; Exit or restructuring costs; Executive or director change31
- Aug 14, 20248-K Results of operations32
- Aug 6, 20248-K Regulation FD disclosure33
- Jul 1, 20248-K Executive or director change34
- Jun 7, 20248-K Shareholder vote35
- May 17, 20248-K Entered a material agreement36
- May 14, 20248-K Results of operations37
- May 2, 20248-K Entered a material agreement; Other events38
- Apr 29, 20248-K Regulation FD disclosure39
- Dec 6, 2022New chief executive Harlan F. Weisman becomes CEO12
- Oct 24, 2019New chief executive Glenn R. Mattes becomes CEO13
- Dec 31, 2016Founded TFF Pharmaceuticals, Inc. is founded2
Calendar
When it reported results
- Aug 14, 2024Reported quarterly or annual results32
- May 14, 2024Reported quarterly or annual results37
- Mar 28, 2024Reported quarterly or annual results40
- Nov 14, 2023Reported quarterly or annual results41
- Aug 15, 2023Reported quarterly or annual results42
- May 11, 2023Reported quarterly or annual results43
- Mar 7, 2023Reported quarterly or annual results44
- Nov 14, 2022Reported quarterly or annual results45
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
181 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 45 major events, 56 insider forms, 13 large holders, 1 private raises, 53 other. The latest 20:
- Mar 7, 2025EFFECT EDGAR
- Mar 7, 2025EFFECT EDGAR
- Mar 7, 2025EFFECT EDGAR
- Mar 7, 2025EFFECT EDGAR
- Mar 6, 202525 EDGAR
- Mar 6, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
- Mar 6, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
- Mar 6, 2025S-8 POS POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 EDGAR
- Mar 6, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
- Mar 6, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
- Mar 6, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
- Mar 6, 2025POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 EDGAR
- Mar 6, 20258-K CURRENT REPORT EDGAR
- Feb 4, 2025DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
- Feb 3, 20258-K CURRENT REPORT EDGAR
- Dec 23, 2024DEF 14A PROXY STATEMENT EDGAR
- Dec 11, 2024PRE 14A PROXY STATEMENT EDGAR
- Dec 10, 20248-K CURRENT REPORT EDGAR
- Nov 20, 202410-Q QUARTERLY REPORT EDGAR
- Nov 19, 2024SC 13G/A EDGAR
The 181 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
25 open-market trades by officers, directors and large owners since October 2021: 22 buys and 3 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 16, 2023 | Carlson Clint Duane10% owner | Sale | 1,000 | $0.39 | $390 | Form 4 |
| Aug 15, 2023 | Weisman Harlan FPresident and CEO | Buy | 600,000 | $0.25 | $150.0K | Form 4 |
| Aug 15, 2023 | ROCAMBOLI STEPHENDirector | Buy | 20,000 | $0.25 | $5.0K | Form 4 |
| Aug 15, 2023 | Roberts BrandiDirector | Buy | 20,000 | $0.25 | $5.0K | Form 4 |
| Aug 15, 2023 | MILLS ROBERT SDirector | Buy | 40,000 | $0.25 | $10.0K | Form 4 |
| Aug 15, 2023 | COLEMAN KIRK ALLENChief Financial Officer | Buy | 20,000 | $0.25 | $5.0K | Form 4 |
| Aug 15, 2023 | Mikhak ZamanehChief Medical Officer | Buy | 120,000 | $0.25 | $30.0K | Form 4 |
| Aug 15, 2023 | Carlson Clint Duane10% owner | Sale | 215,000 | $0.44 | $94.6K | Form 4 |
| Mar 10, 2023 | ROCAMBOLI STEPHENDirector | Buy | 13,000 | $0.80 | $10.4K | Form 4 |
| Mar 10, 2023 | COLEMAN KIRK ALLENChief Financial Officer | Buy | 12,000 | $0.79 | $9.5K | Form 4 |
| Mar 10, 2023 | Weisman Harlan FPresident and CEO | Buy | 150,000 | $0.88 | $132.0K | Form 4 |
| Mar 10, 2023 | Mikhak ZamanehChief Medical Officer | Buy | 15,000 | $0.82 | $12.3K | Form 4 |
| Dec 15, 2022 | Weisman Harlan FPresident and CEO | Buy | 50,000 | $1.06 | $53.0K | Form 4 |
| Nov 22, 2022 | Fletcher Aaron G.L.Director | Buy | 43,470 | $1.15 | $50.0K | Form 4 |
| Sep 29, 2022 | THURMAN RANDY HDirector | Sale | 40,255 | $4.29 | $172.7K | Form 4 |
| May 20, 2022 | Weisman Harlan FPresident and CEO | Buy | 4,615 | $5.50 | $25.4K | Form 4 |
| May 18, 2022 | Weisman Harlan FPresident and CEO | Buy | 2,500 | $5.12 | $12.8K | Form 4 |
| May 17, 2022 | Fletcher Aaron G.L.Director | Buy | 24,600 | $5.08 | $125.0K | Form 4 |
| May 17, 2022 | COLEMAN KIRK ALLENChief Financial Officer | Buy | 425 | $4.83 | $2.1K | Form 4 |
| May 16, 2022 | Fletcher Aaron G.L.Director | Buy | 85,000 | $4.86 | $413.1K | Form 4 |
All 25 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Carlson Capital, L.P.SC 13G/A, 4 filings Nov 28, 2022 to Nov 19, 202446
- ARMISTICE CAPITAL, LLCSC 13G, 1 filing Nov 14, 202447
- INTRACOASTAL CAPITAL, LLCSC 13G, 1 filing May 8, 202448
- Laurence W. LyttonSC 13G/A, 3 filings Nov 23, 2022 to Feb 14, 202449
- Lung Therapeutics, Inc.SC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202350
- Corriente Advisors, LLCSC 13G/A, 1 filing Feb 14, 202251
- Nantahala Capital Management, LLCSC 13G/A, 1 filing Feb 14, 202252
Money raised
Private offerings the company reported to the SEC on Form D.
- Mar 22, 2024Filed a private offering of securities Form D: $1.2 million offered in all Form D
SEC filer profile
How TFF Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARTFF Pharmaceuticals, Inc.1
- CIK0001733413
- Employer ID (EIN)82-43447371
- Filer status<br>emerging growth company1
- Incorporated inDelaware1
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address2600 Via Fortuna, Suite 360, Austin, TX 787461
- Phone737-802-19731
- Shares outstanding4,443,041 as of Nov 18, 202411
- Public float$16.5M as of Jun 30, 20235
- On EDGAR sinceMar 27, 20181
- Filings317 in all: 4 (106), 8-K (60), 3 (17), 10-Q (16), 424B5 (13), EFFECT (10), SC 13G/A (10), CORRESP (9)1
All 34 form types
UPLOAD (8), DEF 14A (7), SC 13G (7), 10-K (5), S-1/A (5), D (4), DEFA14A (4), POS AM (4), S-1 (4), PRE 14A (3), S-8 (3), S-8 POS (3), 10-K/A (2), 424B4 (2), ARS (2), S-3 (2), S-3/A (2), 25 (1), 4/A (1), 8-A12B (1), CERT (1), DRS (1), DRS/A (1), DRSLTR (1), FWP (1), NT 10-Q (1)
- Latest filingsAnnual report (10-K) Mar 28, 2024
Quarterly report (10-Q) Nov 20, 2024
Proxy statement (DEF 14A) Dec 23, 2024
Latest 8-K (8-K) Mar 6, 2025
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARCatherine Chai-Zon Lee, Board member
- 19SEC EDGARMichael A. Patane, Board member
- 20SEC EDGARThomas Braxton King, Board member
- 21SEC EDGARBrandi Roberts, Board member
- 22SEC EDGARMalcolm Fairbairn, Board member
- 23SEC EDGARAaron G.l. Fletcher, Board member
- 24SEC EDGARHarlan F. Weisman, Board member
- 25SEC EDGARRandy H. Thurman, Board member
- 26SEC EDGARRobert S. Mills, Board member
- 27SEC EDGARStephen Rocamboli, Board member
- 28SEC EDGARShareholder vote
- 29
- 30SEC EDGARListing notice or transfer
- 31
- 32SEC EDGARResults of operations
- 33SEC EDGARRegulation FD disclosure
- 34SEC EDGARExecutive or director change
- 35SEC EDGARShareholder vote
- 36SEC EDGAREntered a material agreement
- 37SEC EDGARResults of operations
- 38
- 39SEC EDGARRegulation FD disclosure
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52